Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patricia R Hebert

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Archives of Internal Medicine|May 12, 2004
Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population: a review and qualitative overview of the prospective cohort studiesAlicia Montanez, Jeremy N Ruskin, Patricia R Hebert, et al.
Therapeutic Innovation & Regulatory Science|September 5, 2018
Benefits and Risks of Nonsteroidal Anti-inflammatory Drugs: Methodologic Limitations Lead to Clinical UncertaintiesManas A Rane, Jennifer G Foster, Sarah K Wood, et al.
American Heart Journal|May 4, 2010
Hypothesis formulation from subgroup analyses: nonadherence or nonsteroidal anti-inflammatory drug use explains the lack of clinical benefit of aspirin on first myocardial infarction attributed to "aspirin resistance"Charles H Hennekens, Wendy R Schneider, Patricia R Hebert, et al.
Journal of General Internal Medicine|October 6, 2010
Control of health care-associated infections (HAI): winning both the battles and the warN Joel Ehrenkranz, Ann T MacIntyre, Patricia R Hebert, et al.
Contemporary Clinical Trials|July 6, 2010
Academic perspectives on the United States Food and Drug Administration's guidance for industry on diabetes mellitusCharles H Hennekens, Patricia R Hebert, Wendy R Schneider, et al.
JAMA|July 16, 2002
Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunctionDennis T Ko, Patricia R Hebert, Christopher S Coffey, et al.
Nutrition (Burbank, Los Angeles County, Calif.)|December 31, 2003
Reporting of model validation procedures in human studies of genetic interactionsChristopher S Coffey, Patricia R Hebert, Harlan M Krumholz, et al.
Archives of Internal Medicine|July 14, 2004
Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trialsDennis T Ko, Patricia R Hebert, Christopher S Coffey, et al.
Cardiology Research and Practice|May 12, 2011
The Association of the Metabolic Syndrome with PAI-1 and t-PA LevelsChristopher S Coffey, Folkert W Asselbergs, Patricia R Hebert, et al.
Plos One|September 22, 2010
Cardiovascular risk associated with interactions among polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systemsJohn P Bentley, Folkert W Asselbergs, Christopher S Coffey, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Archives of Internal Medicine|May 12, 2004
Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population: a review and qualitative overview of the prospective cohort studiesAlicia Montanez, Jeremy N Ruskin, Patricia R Hebert, et al.
Therapeutic Innovation & Regulatory Science|September 5, 2018
Benefits and Risks of Nonsteroidal Anti-inflammatory Drugs: Methodologic Limitations Lead to Clinical UncertaintiesManas A Rane, Jennifer G Foster, Sarah K Wood, et al.
American Heart Journal|May 4, 2010
Hypothesis formulation from subgroup analyses: nonadherence or nonsteroidal anti-inflammatory drug use explains the lack of clinical benefit of aspirin on first myocardial infarction attributed to "aspirin resistance"Charles H Hennekens, Wendy R Schneider, Patricia R Hebert, et al.
Journal of General Internal Medicine|October 6, 2010
Control of health care-associated infections (HAI): winning both the battles and the warN Joel Ehrenkranz, Ann T MacIntyre, Patricia R Hebert, et al.
Contemporary Clinical Trials|July 6, 2010
Academic perspectives on the United States Food and Drug Administration's guidance for industry on diabetes mellitusCharles H Hennekens, Patricia R Hebert, Wendy R Schneider, et al.
JAMA|July 16, 2002
Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunctionDennis T Ko, Patricia R Hebert, Christopher S Coffey, et al.
Nutrition (Burbank, Los Angeles County, Calif.)|December 31, 2003
Reporting of model validation procedures in human studies of genetic interactionsChristopher S Coffey, Patricia R Hebert, Harlan M Krumholz, et al.
Archives of Internal Medicine|July 14, 2004
Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trialsDennis T Ko, Patricia R Hebert, Christopher S Coffey, et al.
Cardiology Research and Practice|May 12, 2011
The Association of the Metabolic Syndrome with PAI-1 and t-PA LevelsChristopher S Coffey, Folkert W Asselbergs, Patricia R Hebert, et al.
Plos One|September 22, 2010
Cardiovascular risk associated with interactions among polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systemsJohn P Bentley, Folkert W Asselbergs, Christopher S Coffey, et al.
Pageof 3